Source: Annual Congress 2004 - Management of infection and tuberculous diseases II
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
J. M. Garcia-Garcia, F. Alvarez-Navascues, Z. Bastardo, M. Sanchez-Fernandez, A. Sanchez-Antuna, M. Martinez-Muniz, M. Garcia-Marron, H. Villar, J. M. F.-Carreira (Aviles, Aviles. Asturias, Spain). Tuberculosis: follow-up of treatment without directed observed therapy (DOT) in a sanitary area. Eur Respir J 2004; 24: Suppl. 48, 3961

Member's Comments

No comment yet.

Related content which might interest you: DOT versus self administration in TB treatment in pilot area of sector 4, Bucharest- 3 years early re-treatment analysis Source: Eur Respir J 2004; 24: Suppl. 48, 362s Year: 2004 Treatment outcomes of tuberculosis patients under directly observed therapy (DOT) for three years Source: Eur Respir J 2004; 24: Suppl. 48, 653s Year: 2004 Prevention of latent TB reactivation in rheumatology patients prior to anti-TNF therapy: Evaluation of a risk stratification strategy in a low prevalence area Source: International Congress 2015 – Screening strategies in TB Year: 2015 Do we need to screen for latent TB when initiating a methotrexate treatment? Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection: diagnosis and treatment Year: 2013 Adherence to the recommendation of prescribing 4 drugs in the intensive phase of the standard treatment of tuberculosis in Spain Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 3 Year: 2014 Tuberculosis (TB), mortality - efficiency of new control / treatment strategies Source: Annual Congress 2003 - Control of tuberculosis Year: 2003 To study outcome of directly observered treatment shortcourse (DOTS) category I and category II relapses when put on re-treatment regimen (Cat-II DOTS) Source: Annual Congress 2011 - Tuberculosis epidemiology and public health Year: 2011 Treatment of multidrug-resistant tuberculosis (MDR-TB) with modified shorter all-oral treatment regimen (mSTR) under operational research conditions in Belarus Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020 Experience of managing TB/HIV infection in a regional UK center over a 5 year period Source: International Congress 2016 – Non-tuberculous mycobacteria: HIV-TB co-infection and adenosine deaminase (ADA) Year: 2016 Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016 Screening coverage and treatment loss to follow-up of Diabetes and Tuberculosis (TB) patients in hospitals with measures to integrate care of Diabetes and TB and those without integration measures in Malawi Source: Virtual Congress 2020 – Tuberculosis and comorbidities Year: 2020 Impact of pre-treatment duration by first line drugs on treatment outcomes of patients with MDR-TB Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 A novel nurse-led approach improves treatment completion rates for latent tuberculosis infection (LTBI) treatment Source: International Congress 2014 – Mycobacterium tuberculosis infection: new therapeutic approaches Year: 2014 Impact of social support programme on MDR-TB patients' treatment outcomes Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 3 Year: 2014 Tuberculosis and intravenous drug users, impact of proximity measures in screening and treatment Source: International Congress 2015 – Screening strategies in TB Year: 2015 Is it necessary to give tuberculosis treatment daily throughout? Source: International Congress 2014 – Mycobacterium tuberculosis infection and disease: clinical epidemiology 1 Year: 2014 Effectiveness of mandatory treatment for tuberculosis - An observational registry study Source: Annual Congress 2013 –Epidemiological and public health features of tuberculosis Year: 2013 A comparison of on-site versus remote physician follow up of directly observed preventive treatment (DOPT) for latent tuberculosis infection (LTBI) on completion rates Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology II Year: 2012 Patients over 35 years experience more side-effects during latent TB treatment: Experience from an urban hospital with a high incidence of Tuberculosis Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Preventing MDRTB in Europe: Drug sensitivities received after the initial phase of treatment Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016